A Klass Drugs And Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 08-12-2024
- Paid Up Capital ₹ 1.82 M
as on 08-12-2024
- Company Age 29 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.10 Cr
as on 08-12-2024
- Revenue -18.43%
(FY 2023)
- Profit -36.48%
(FY 2023)
- Ebitda 22.21%
(FY 2023)
- Net Worth 37.93%
(FY 2023)
- Total Assets 2.99%
(FY 2023)
About A Klass Drugs And Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.82 M.
The company currently has active open charges totaling ₹1.10 Cr.
Anil Navandar and Krishnakumar Bhattad serve as directors at the Company.
- CIN/LLPIN
U24230MH1995PTC093408
- Company No.
093408
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Oct 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Buldhana, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at A Klass Drugs And Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Navandar  | Whole-Time Director | 09-Oct-1995 | Current |
| Krishnakumar Bhattad | Whole-Time Director | 09-Oct-1995 | Current |
Financial Performance and Corporate Structure Insights of A Klass Drugs And Pharmaceuticals.
A Klass Drugs And Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 18.43% decrease. The company also saw a substantial fall in profitability, with a 36.48% decrease in profit. The company's net worth Soared by an impressive increase of 37.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of A Klass Drugs And Pharmaceuticals?
Unlock access to A Klass Drugs And Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 03 Aug 2021 | ₹1.10 Cr | Open |
How Many Employees Work at A Klass Drugs And Pharmaceuticals?
Unlock and access historical data on people associated with A Klass Drugs And Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of A Klass Drugs And Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped A Klass Drugs And Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
